Previous 10 | Next 10 |
2023-08-10 10:50:41 ET MeiraGTx press release ( NASDAQ: MGTX ): Q2 GAAP EPS of -$0.53. Revenue of $3.5M. Cash and cash equivalents were $92.8 million as of June 30, 2023, compared to $115.5 million as of December 31, 2022. For further details see: MeiraGTx GA...
Phase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) enrollment target has now been surpassed Announced positive clinical data from the completed AQUAx Phase 1 study of AAV2-hAQP1 fo...
LONDON and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced a poster presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-oncolog...
LONDON and NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that after a successful inspection by the Irish Health Products Regulatory Authority (HPRA), it has received a Commercial Manu...
2023-06-23 17:09:25 ET Gainers: Morningstar ( MORN ) +8% . Annexon ( ANNX ) +5% . Cardlytics ( CDLX ) +4% . MeiraGTx Holdings ( MGTX ) +4% . Lexicon Pharmaceuticals ( LXRX ) +3% . Losers: Lulu's Fashion Lounge ( L...
LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company’s AAV-hAQP1 clinical program f...
LONDON and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit nine poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2023...
2023-05-11 09:55:38 ET MeiraGTx press release ( NASDAQ: MGTX ): Q1 GAAP EPS of -$0.62 beats by $0.04 . Revenue of $3.33M (-40.9% Y/Y) misses by $1.54M . For further details see: MeiraGTx GAAP EPS of -$0.62 beats by $0.04, revenue of $3.33M misses by $1.54M
Raised approximately $60 million in a private placement in May 2023 with investors consisting of several of the Company’s top shareholders On track for BLA submission of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pig...
2023-05-03 09:13:39 ET Gene therapy company MeiraGTx Holdings ( NASDAQ: MGTX ) has agreed to sell ~10.7M shares at $5.75 per share for aggregate gross proceeds of ~$60M. The company intends to use the proceeds to continue to advance its pipeline of gene therapy assets, as well...
News, Short Squeeze, Breakout and More Instantly...
MeiraGTx Holdings plc Company Name:
MGTX Stock Symbol:
NASDAQ Market:
MeiraGTx Holdings plc Website:
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Received $50 million milestone following initiation of the extension study for the Ph...
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held f...
2024-04-17 00:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...